Navidea Biopharmaceuticals, Inc. (NYSE:NAVB)
Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) represented a move of 0 percent or $0.01 per share and closed its previous day trading session at $0.19. 0 Shares were traded in the last trading session with an Average Volume of 518.02 Million Shares. The stock currently has a Market Capitalization of 35.66 Million.
Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents for diseases such as cancer and Alzheimer. The Company’s radiopharmaceutical development programs include: Lymphoseek(R), AZD4694 and RIGScan(TM). Navidea Biopharmaceuticals, Inc., formerly Neoprobe Corporation, is headquartered in Dublin, Ohio.
The stock traded between $0.130 and $0.470 over 1-Year time period showing its price to sales ratio of 25.47. Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) is currently showing an DECREASING volatility over a period of 10-Days while the 20-Days Volatility showing a DECREASING trend.
Right now, the stock has a 50-Day Simple Moving Average of $-21.18 and 200-Day Simple Moving Average of $-25.51. Its Price to Free Cash Flow is 0 and Price to Book of 18.5.
Analyst’s recommended the stock as 5 where 1 represents Strong Buy and 5 represents Sell.
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB)
In the last trading session, Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) added its value by 0% closing at the price of $0.63. The stock currently has market capitalization of 46.95 Million, with average volume of 809.01 Million shares.
Beta is also a factor of measure of the relative volatility of a particular stock to the market. Currently Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) is showing beta of 0.8. This particular value of beta suggests that Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) has historically moved 80% for every 100% move in the benchmark, based on price level.
EPS is another important factor while making the decision of buying, selling or holding of particular share. Currently EPS for Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) is at $-0.8.
The stock currently has RSI of 46.61. RSI is considered overbought when above 70 and oversold when below 30, currently the given RSI for the stock suggests that the stock is average and it has not entered in overbought or oversold territory.
Catabasis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of therapeutics for treatment of inflammatory, immunological and metabolic diseases. Its product development pipeline includes CAT-1004, CAT-2000 series including CAT-2054 and CAT-2003, CAT-4001 as well as various programs which are in different clinical-stage. Catabasis Pharmaceuticals, Inc. is based in Cambridge, Massachusetts.
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) topped its 52-week high price of $2.380 on 02/13/18 and 52-Week Low Price of $0.530 on 11/21/18. The Stock currently has P/E (price to earnings ttm) of 0 and Weekly volatility of 6.74% and monthly volatility of 7.55% respectively.